We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.
- Authors
Topp, Max S; Kufer, Peter; Gökbuget, Nicola; Goebeler, Mariele; Klinger, Matthias; Neumann, Svenja; Horst, Heinz-A; Raff, Thorsten; Viardot, Andreas; Schmid, Mathias; Stelljes, Matthias; Schaich, Markus; Degenhard, Evelyn; Köhne-Volland, Rudolf; Brüggemann, Monika; Ottmann, Oliver; Pfeifer, Heike; Burmeister, Thomas; Nagorsen, Dirk; Schmidt, Margit; Lutterbuese, Ralf; Reinhardt, Carsten; Baeuerle, Patrick A; Kneba, Michael; Einsele, Hermann; Riethmüller, Gert; Hoelzer, Dieter; Zugmaier, Gerhard; Bargou, Ralf C
- Abstract
Blinatumomab, a bispecific single-chain antibody targeting the CD19 antigen, is a member of a novel class of antibodies that redirect T cells for selective lysis of tumor cells. In acute lymphoblastic leukemia (ALL), persistence or relapse of minimal residual disease (MRD) after chemotherapy indicates resistance to chemotherapy and results in hematologic relapse. A phase II clinical study was conducted to determine the efficacy of blinatumomab in MRD-positive B-lineage ALL.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Vol 29, Issue 18, p2493
- ISSN
1527-7755
- Publication type
Journal Article
- DOI
10.1200/JCO.2010.32.7270